Dr Oana M Lungu, MD | |
85 Herrick St, Beverly Hospital, Beverly, MA 01915-1790 | |
(978) 922-3000 | |
Not Available |
Full Name | Dr Oana M Lungu |
---|---|
Gender | Female |
Speciality | Internal Medicine |
Experience | 33 Years |
Location | 85 Herrick St, Beverly, Massachusetts |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1295820876 | NPI | - | NPPES |
001516008 | Medicaid | NV | |
110078683A | Medicaid | MA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208M00000X | Hospitalist | 231084 (Massachusetts) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Northeast Hospital Corporation | Beverly, MA | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Lahey Clinic Inc | 2264336528 | 1211 |
News Archive
Tens of millions of Americans - an estimated 1 to 2 percent of the population - will suffer at some point in their lifetimes from obsessive-compulsive disorder, a disorder characterized by recurrent, intrusive, and disturbing thoughts (obsessions), and/or stereotyped recurrent behaviors (compulsions).
The U.S. Food and Drug Administration yesterday (11th of April 2018), released a statement approving the marketing of world's first artificial intelligence using medical device that can detect diabetic retinopathy among diabetic patients.
TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today successful results of a Phase I clinical trial of its self-applied ViaDerm-Calcitonin product for the treatment of musculoskeletal disorders such as osteoarthritis and musculoskeletal pain.
Investigators at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) have found evidence that continues to implicate insulin-like growth factor receptor (IGF-1R) in the development of Graves' disease.
› Verified 7 days ago
Entity Name | Lahey Clinic Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1538194980 PECOS PAC ID: 2264336528 Enrollment ID: O20031120000097 |
News Archive
Tens of millions of Americans - an estimated 1 to 2 percent of the population - will suffer at some point in their lifetimes from obsessive-compulsive disorder, a disorder characterized by recurrent, intrusive, and disturbing thoughts (obsessions), and/or stereotyped recurrent behaviors (compulsions).
The U.S. Food and Drug Administration yesterday (11th of April 2018), released a statement approving the marketing of world's first artificial intelligence using medical device that can detect diabetic retinopathy among diabetic patients.
TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today successful results of a Phase I clinical trial of its self-applied ViaDerm-Calcitonin product for the treatment of musculoskeletal disorders such as osteoarthritis and musculoskeletal pain.
Investigators at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) have found evidence that continues to implicate insulin-like growth factor receptor (IGF-1R) in the development of Graves' disease.
› Verified 7 days ago
Entity Name | Lahey Clinic Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1063447316 PECOS PAC ID: 2264336528 Enrollment ID: O20040629001269 |
News Archive
Tens of millions of Americans - an estimated 1 to 2 percent of the population - will suffer at some point in their lifetimes from obsessive-compulsive disorder, a disorder characterized by recurrent, intrusive, and disturbing thoughts (obsessions), and/or stereotyped recurrent behaviors (compulsions).
The U.S. Food and Drug Administration yesterday (11th of April 2018), released a statement approving the marketing of world's first artificial intelligence using medical device that can detect diabetic retinopathy among diabetic patients.
TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today successful results of a Phase I clinical trial of its self-applied ViaDerm-Calcitonin product for the treatment of musculoskeletal disorders such as osteoarthritis and musculoskeletal pain.
Investigators at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) have found evidence that continues to implicate insulin-like growth factor receptor (IGF-1R) in the development of Graves' disease.
› Verified 7 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Oana M Lungu, MD 85 Herrick St, Beverly Hospital, Beverly, MA 01915-1790 Ph: (978) 922-3000 | Dr Oana M Lungu, MD 85 Herrick St, Beverly Hospital, Beverly, MA 01915-1790 Ph: (978) 922-3000 |
News Archive
Tens of millions of Americans - an estimated 1 to 2 percent of the population - will suffer at some point in their lifetimes from obsessive-compulsive disorder, a disorder characterized by recurrent, intrusive, and disturbing thoughts (obsessions), and/or stereotyped recurrent behaviors (compulsions).
The U.S. Food and Drug Administration yesterday (11th of April 2018), released a statement approving the marketing of world's first artificial intelligence using medical device that can detect diabetic retinopathy among diabetic patients.
TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today successful results of a Phase I clinical trial of its self-applied ViaDerm-Calcitonin product for the treatment of musculoskeletal disorders such as osteoarthritis and musculoskeletal pain.
Investigators at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) have found evidence that continues to implicate insulin-like growth factor receptor (IGF-1R) in the development of Graves' disease.
› Verified 7 days ago
Dr. Robert John Tavares, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 85 Herrick St, Lahey At Beverly Hospital, Beverly, MA 01915 Phone: 978-922-3000 Fax: 978-816-3052 | |
Elias Massoud, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 85 Herrick St, Beverly, MA 01915 Phone: 978-922-3000 | |
Dr. James L Perkins Jr., M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 85 Herrick Street, Beverly, MA 01915 Phone: 978-922-3000 | |
Dr. Gaurav Parikh, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 85 Herrick St, Beverly, MA 01915 Phone: 978-922-3000 Fax: 888-646-4525 | |
Meher A Ahmed, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: Beverly Hospital, 85 Herrick Street, Beverly, MA 01915 Phone: 978-922-3000 | |
Dr. Michail M. Orlov, M.D. Hospitalist Medicare: Medicare Enrolled Practice Location: Beverly Hospital, 85 Herrick Street, Beverly, MA 01915 Phone: 789-922-3000 Fax: 978-921-7048 |